Scientific activity and scientific production
"Cima's scientific activity has generated publications in journals of high scientific impact, patented biomedical inventions and coordination in international projects."
ANTONIO PINEDA
SCIENTIFIC DIRECTOR. CIMA UNIVERSIDAD DE NAVARRA
2022-2023 in data
301
scientific publications in total
487
professionals work at Cima
244
scientific publications
in the first quartile
56
Collaboration agreements
13,26
average impact factor
with authorship
+600
national and international
media coverage
with authorship
More information
Outstanding scientific publications
Year 2022
|
|
|
Alonso MM et al. New England Journal of Medicine. |
| Pastor F. Molecular Cancer. División de Innovación Tecnológica Primer decil. Top 3 |
|
|
|
Pastor F. Molecular Cancer. |
|
|
| Berraondo P et al. Annals of Oncology. División de Cáncer Primer decil. |
|
|
| Calvo A et al. Nature Medicine División de Cáncer Primer decil. Top 3 |
|
|
| San Miguel J et al. Journal of Clinical Oncology. División de Cáncer Primer decil |
|
|
| Diez J et al. European Heart Journal. División Cardiovascular Primer decil. Top 3 |
| Paiva B et al. Journal of ClinicalOncology. División de Cáncer Primer decil. |
| Lecanda F et al. Cancer Discovery. Colaboración Dr. Vicent División de Cáncer Primer decil |
|
|
| San Miguel J et al. The Lancet Haematology. División de Cáncer Primer decil. Top 3 |
|
|
| Melero I et al. Cancer Discovery División de Cáncer Primer decil. |
| Odero MD et al. Blood. División de Cáncer Primer decil. Top 3 |
| Prósper F et al. Cell Metabolism. División de Cáncer Primer decil. Top 3 |
| Fontanellas A et al. Science Traslational Medicine. División de Cáncer Primer decil. Top 3 |
|
|
| Dubrot J et al. Nature Immunology División de Cáncer Primer decil. |
|
|
| Ortiz de Solórzano C et al. Medical Image Analysis División de Innovación Tecnológica Primer decil. Top 3 |
Scientific activity of the
Cima Universidad de Navarra
Latest scientific publications
- FKBP51 inhibition ameliorates neurodegeneration and motor dysfunction in the neuromelanin-SNCA mouse model of Parkinson's disease Mar 5, 2025 | Magazine: Molecular Therapy
- The C5a/C5aR1 axis promotes migration of tolerogenic dendritic cells to lymph nodes, impairing the anticancer immune response Mar 4, 2025 | Magazine: Cancer Immunology Research
- 4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models Feb 11, 2025 | Magazine: Journal for ImmunoTherapy of Cancer
- FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis Jan 27, 2025 | Magazine: Journal of Translational Medicine